Erectile dysfunction is a prevalent disorder that not only affects men with the disorder but also their partners. Significant improvements in the sexual health of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. Currently PDE5 inhibitors are used on an on-demand basis. New evidence regarding the effects of PDE5 inhibitors on the underlying pathophysiologic processes that cause erectile dysfunction have sparked interest in the continuous dosing of these medications. We will discuss the biological background and the available clinical evidence for the continuous use of phosphodiesterase inhibitors in erectile dysfunction. Lastly, we will discuss the emerging clinical data for the use of daily PDE5 inhibitors in men with lower urinary tract symptoms.
Introduction
Erectile dysfunction (ED) affects over 18 million couples in the United States alone. 1 The causes of ED involve psychiatric, hormonal, vascular and neurologic conditions. Psychiatric and hormonal imbalances are often effectively treated by correcting the underlying psychiatric disease or endocrinopathy. Vascular causes include those that affect the arterial inflow to the penis or its venous outflow. Neurological problems are often due to diabetes or other systemic diseases that are often difficult to cure. One of the most important neurological causes of ED is injury to the cavernosal nerves during pelvic surgery. 2 The use of phosphodiesterase 5 (PDE5) inhibitors on an on-demand basis has improved the sexual function of many of these patients but there continue to be others with minimal or no improvement. 3 There has been an increased interest in changing the dosing regimens using current phosphodiesterase (PDE) inhibitors in an attempt to improve the return of erectile function in these difficult-to-treat patients.
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Pathophysiology of erectile dysfunction
For an erection to occur several physiologic processes and structures must function appropriately together. Injury to any one of these structures or processes can lead to ED. A physiologic erection is caused by cavernosal smooth muscle relaxation, cavernosal artery dilatation and venous outflow compression. 6 Therefore, injury to the smooth muscle, the arteries, or the venous outflow can all lead to ED. Venous outflow compression is a passive phenomenon dependent on the relaxation of the cavernosal smooth muscle and subsequent compression of the subtunical veins against the tunica albuginea. Thus, venous dysfunction is primarily a symptom of smooth muscle dysfunction. Cavernosal smooth muscle appears to be one of the most important variables in determining erectile function.
A decrease in the number of cavernosal smooth muscle cells has been noted in previous studies of ED. 7 Smooth muscle content is typically measured by acquiring cavernosal tissue from biopsies and staining them. The percentage area of the cavernosal tissue that is composed of smooth muscle is then calculated with the aid of computerized digital image analysis. The more cavernosal smooth muscle tissue a subject has the less likely that the subject will suffer from ED. Another method used is quantitative immunohistochemical staining for acting or other smooth muscle proteins. Similarly, the more smooth muscle protein content, the less likely the subject will have ED. 8 The most important neurotransmitter for cavernosal smooth muscle relaxation is nitric oxide. 9 Nitric oxide mediates production of guanosine monophosphate (cGMP), which causes a decrease in the intracellular levels of calcium, leading to cavernosal smooth muscle relaxation. A lack of bioavailable nitric oxide has been shown to be associated with decreased relaxation of cavernosal tissue in models of ED. 10 Nitric oxide is typically evaluated by measuring levels of nitric oxide synthase (NOS). In fact, gene transfer of endothelial NOS has been shown to improve erectile function in diabetic rat models. 11 Form these and other studies researchers have therefore started to focus on NOS and the content of smooth muscle as targets for measuring improvement in the different treatment options for ED.
Aging, diabetes and hypertension are known to have strong associations with the development of ED. 12 The collagen content within the cavernosal tissues has been studied in animal models. Salama et al. 13 reported on increased density of collagen bundles in aged and diabetic rat models. A similar study looking at the structural changes in the corpora cavernosum of hypertensive rats found similar results with respect to the increased collagen content. This second study also found that the elastic tissue within the corporeal bodies showed an inverse relationship with blood pressure. 14 Although changes in collagen content have been found in animal models of ED, human studies do not show such a clear relationship. 15 Fibrosis and increased collagen content do not appear to be as strong a predictor of erectile function as smooth muscle function or smooth muscle content.
Biological evidence supporting the use continuous PDE5 inhibitors
Animal studies have shown that daily administration of PDE5 inhibitors can lead to improvements in the physiologic functioning of the erectile tissue. De Young et al. 16 demonstrated that intracavernosal pressure in rats treated with daily sildenafil was improved significantly from the control groups. These results were corroborated in a similar study looking at a novel PDE5 inhibitor in which the rats treated with the highest dose were found to have increased cavernosal pressures during electrostimulation of the cavernosal nerves. 17 This group was also able to show decreased transforming growth factor (TGF)-b1 expression in a subsequent study with higher doses of the PDE inhibitor. This implies that PDE5 inhibitors may prevent fibrosis of the corporal tissue in men with ED by decreasing the release of the profibrotic growth factor TGF-b1. PDE5 inhibitors are thought to have an antifibrotic effect on the corporal tissue by inducing NOS. The increased levels of cGMP are thought to downregulate TGF-b1 protein expression and its downstream effects such as myofibroblast differentiation. 18 Other animal studies have shown that the chronic use of PDE5 inhibitors can potentially improve smooth muscle content and function in several models of ED as well. A study looking at a cavernosal nerve injury model found that vardenafil was able to improve smooth muscle function as measured by NOS and smooth muscle content. Interestingly, this study also found that vardenafil increased cell replication of the smooth muscle as measured by immunohistochemical staining of proliferating cell nuclear antigen. 19 Additionally, a decrease in the cellular apoptotic rate was not seen. Vardenafil appears to increase proliferation of smooth muscle cells but does not prevent apoptosis of these cells. This may indicate a rationale for the chronic administration of PDE5 inhibitors. Another study in an aged rat model with daily use of PDE inhibitors showed very similar results. 20 Lastly, in diabetic models of ED increased smooth muscle function with chronic therapy has also been found. 21 Clinical evidence supporting the use of daily PDE5 inhibitors
To date several animal studies have found that the physiologic, morphologic and cellular changes that occur in ED can be further improved with chronic administration of PDE5 inhibitors. Emerging clinical evidence indicates that this may also be the case in humans. When initiating new dosing strategies, overall safety is always a primary concern. Like all medical treatments PDE5 inhibitors have side effects that can potentially harm some of its users. The safety of potentially vulnerable patients to chronic therapy has been evaluated extensively. Debusk et al. 22 evaluated patients with stable angina for 12 weeks and found no increase in serious adverse effects. Similarly, Katz et al. 23 found that subjects with stable heart failure tolerated the medications without an increase in serious cardiac events.
Long-term treatments are more costly and require more effort to study. Fortunately, tachyphylaxis with PDE5 inhibitors does not appear to occur. Muscki et al. 24 used a scheduled dosing regimen and PDE5 inhibitors in ED and urinary tract symptoms H Pimentel et al measured PDE5 expression and erection physiology after chronic treatment with sildenafil. In this study the maximal intracavernosal pressure after sildenafil did not significantly decrease after long-term treatment. The activity of the PDE enzyme continued to be suppressed at similar efficacy as well. Both of these results support other evidence that tachyphylaxis does not occur with chronic treatment. It is well established that fewer patients achieve adequate erectile function after radical prostatectomy. 25 Therefore, postprostatectomy patients have become a main target for new dosing regimens. Previous studies focusing on vacuum erection devices and alprostadil injections have found that continuous dosing improves return of erectile function. 26, 27 Montorsi et al. 26 measured a spontaneous erection rate of 67 versus 20% for those subjects who where initiated on the early frequent dosing of alprostadil injections in comparison to the control group. Although scheduled treatment with alprostadil injections and vacuum erection devices have been found to be beneficial, the invasiveness and inconvenience of these treatments do not make them ideal candidates for further study.
PDE inhibitors are less invasive and much easier to administer. Nandipati et al. 28 showed that with a combination of scheduled sildenafil tablets and alprostadil injections the incidence of venous leak was diminished. Almost 50% of these patients were also able to achieve a spontaneous erection without treatment after the termination of the study. Schwartz et al. 29 treated postprostatectomy subjects with every other night sildenafil for 6 months and determined that the smooth muscle content within the cavernosal tissue was maintained. More impressively, the group taking the larger 100 mg dose had a significant improvement in the amount of smooth muscle content when compared to there own preoperative levels. This is the only study we are aware of that sampled cavernosal tissue after continuous treatment. The results are very encouraging and indicate that erectile function could potentially be stabilized after radical prostatectomy.
Another group who may benefit significantly from daily dosing would be nonresponders to on-demand PDE5 inhibitor therapy. Patients with previous failure of PDE5 inhibitors are currently counseled on more invasive options such as injection, intraurethral and surgical therapies. McMahon et al. 5 found that a significant proportion of patients who were previously considered tadalafil nonresponders were salvaged with a scheduled dosing treatment plan. Those patients placed on tadalafil 10 mg every 3 days were able to achieve intercourse 58% of the time with this change. Changing the type of PDE5 inhibitors for nonresponders has typically had less drastic results. 30 Another difficult-to-treat group are patients with comorbidities such as coronary artery disease and diabetes. Mirone et al. 31 compared two different dosing regimens in 4262 subjects. The majority of the subjects had at least one of the above comorbidities. The scheduled tadalafil group had more attempted sexual encounters than the on-demand group. Importantly, the dosing regimen was also found to be safe.
Another important factor for some couples is convenience and spontaneity. 31, 32 Daily dosing tadalafil can achieve plasma levels greater than ondemand dosing after as few as 5 days. 33 Porst et al.
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evaluated PDE5 naive patients and found that the 5 and 10 mg daily doses were well tolerated and achieved excellent results in comparison to placebo. Rajfer et al. 35 also found that daily dosing with tadalafil may allow patients to decrease their dose while achieving similar improvements in erectile function. In this study the daily doses were decreased to 2.5 and 5 mg while still achieving significant improvements and a reasonable side effect profile. The Porst and Rajfer studies were limited because they did not include an on-demand treatment arm. One clinical study by McMahon et al. 36 did compare these two groups. McMahon et al. compared 20 mg of on-demand therapy with 10 mg daily. The subjects with daily dosing had better International Index of Erectile Function (IIEF) scores and 15% more subjects were able to successfully have intercourse with their partners in comparison to the on-demand group. Indeed, there is some evidence that daily dosing may provide increased convenience and improved efficacy while still maintaining a minimal side effect profile (Table 1) .
Another emerging use for daily dosing of PDE5 inhibitors is in the treatment of lower urinary tract symptoms. McVary et al. 37 randomized 369 patients with lower urinary tracts symptoms and ED to daily sildenafil or placebo. There were significant improvements in both erectile function and lower urinary tract symptoms in the sildenafil group. The improvements in the lower urinary tract symptoms were comparable to treatments with a-blockade. The use of daily tadalafil in comparison to placebo has also yielded similar results. 38 Kaplan et al.
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compared alfuzosin and sildenafil in patients with both lower urinary tract symptoms and ED. Mean International Prostate Symptom Score (IPSS) and IIEF scores were most improved in the group who had combination therapy. Because there was no placebo group in this trial, a placebo-controlled trial will be necessary before determining if the combination therapy is indeed the most efficacious. As in previous studies with PDE5 inhibitors, there was no improvement in postvoid residuals or flow rates with sildenafil. The mechanism of PDE5 inhibitors to improve lower urinary tract symptoms therefore appears to be different from that of a-blockers. PDE has been found in the prostate of humans but the majority of PDE5 has been found in the glandular stroma. 39 Smooth muscle cGMP protein-dependent kinases have also been found in the transition zone PDE5 inhibitors in ED and urinary tract symptoms H Pimentel et al of the prostate. 40 Filipi et al. 41 measured PDE in bladder tissue. They also found that a PDE-resistant cGMP analog, SP-8-Br-PET-cGMPS, induced a consistent antiproliferative and relaxing effect in bladder tissue. The relaxant tissue and antiproliferative effects on the bladder may lead to a better understanding in how PDE5 inhibitors improve urinary symptoms. Despite the presence of PDE in bladder and prostatic tissues the exact mechanism responsible for the improvement in urinary symptoms has yet to be determined. A possible next step would be to study PDE5 inhibitors in women with urinary symptoms. Evaluating if PDE5 inhibitors can improve urinary symptoms in women may help localize their site of primary action.
Conclusion
There is mounting evidence that daily dosing is preferential in several groups of patients. The groups that will most likely benefit from daily dosing range from postprostatectomy patients to those with concomitant lower urinary symptoms.
The biologic evidence for continuous treatment for ED is significant but the mechanism for why PDE5 inhibitors improve lower urinary tract symptoms is unknown. Further clinical studies are needed to determine what groups will most benefit from this new dosing option. PDE5 inhibitors in ED and urinary tract symptoms H Pimentel et al
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